MSIntuit Suite

Optimize MSI testing

Rule-out MSS cases from the diagnostic workflow by screening with AI for digital pathology

As biomarker screening evolves, AI testing bridges the gaps

MSI status is predictive of response to immunotherapy across all solid tumors.

Evolving guidelines are increasing the number of biomarkers to test for; expanding the diagnostic workflow burden for pathologists and clinicians.

Biopsied tissue is increasingly insufficient to meet the demands of multi-biomarker testing.

Colorectal Adenocarcinoma

CE IVD

In development since 2021

Specimen Type Biopsy and surgical resection

Tested on more than 2500+ patients

50% rule-out with 0.99 NPV

70% rule-out with 0.98 NPV

Colorectal Gastric or GEJ Adenocarcinoma

Undergoing Clinical Validation

In development since 2024

Biopsy

Tested on more than 230+ patients

62% rule-out with 0.99 NPV

Endometrial Carcinoma

Undergoing Clinical Validation

In development since 2024

Specimen Type Biopsy and surgical resection

Tested on more than 230+ patients

21% rule-out with 0.96 NPV

32% rule-out with 0.97 NPV

Solution Type	Specific AI Algorithm/App
Deployment Environment	Clinical Diagnostics
Regulatory Clearance	Colorectal Cancer (dMMR/MSI) – CE-IVD
Target	Colorectal Cancer, Endometrial Cancer, Gastrointestinal (GI) Cancer
Platform Dependency	Platform Agnostic
Deployment Options	Hybrid (Cloud analysis, local viewer)